Đang chuẩn bị liên kết để tải về tài liệu:
Kết quả điều trị ung thư tuyến giáp thể biệt hóa sau phẫu thuật bằng 131I tại Trung tâm Ung bướu Thái Nguyên

Bài viết trình bày đánh giá kết quả điều trị bệnh nhân ung thư tuyến giáp thể biệt hóa sau mổ bằng 131I, nghiên cứu một số yếu tố liên quan đến kết quả điều trị. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả tiến hành trên 87 bệnh nhân ung thư tuyến giáp thể biệt hóa được điều trị tại Trung tâm Ung bướu Thái Nguyên từ năm 2011 đến năm 2018. | NGHIÊN CỨU KHOA HỌC KẾT QUẢ ĐIỀU TRỊ UNG THƯ TUYẾN GIÁP NGHIÊN CỨU KHOA HỌC THỂ BIỆT HÓA SAU PHẪU THUẬT BẰNG 131I SCIENTIFIC RESEARCH TẠI TRUNG TÂM UNG BƯỚU THÁI NGUYÊN The treatment results of differentiated thyroid carcinoma post-thyroidectomy with 131I at Thai Nguyen oncology centre Nguyễn Thành Lam Ngô Thị Tính Vi Trần Doanh Vũ Bích Huyền Trần Bảo Ngọc SUMMARY Objectives 1.To evaluate treatment results of differentiated thyroid carcinoma patients post-thyroidectomy with 131I. 2. To study some factors related to treatment results. Materials and method A descriptive study was conducted on 87 diffentiated thyroid carcinoma patients treated at Thai Nguyen oncology centre from 2011 to 2018. Results Medial age of patients was 47.3 12.7 female male 4.8 1. 67 were papilliary thyroid carcinoma 63.2 had no metastases 32.2 had cervical nodal metastases 4.6 had distant metastases. 95.4 of patients were in stage I II III. Post-operative thyroid remnants were 3.52 1.73 g. The rates of patients responding completely after 1 2 3 and over 3 doses of 131I were 60.9 79.3 87.4 and 92 respectively. Medial total treatment dose of 131I used was 112.5 31.2 mCi medial treatment times were 1.83 0.3 times. In patients with no distant metastases the thyroid remnant ablation of 131I with doses from 30 to 50 mCi was as well as with dose of 100 mCi. The treatment results in patients under 45 years were better than in patients over 45 years in patients with no metastases and cervical nodal metastases were better than in patients with distant metastases in patients in stage I II and III were better than in patients in stage IV in patients with thyroid remnants lt 2 g were better than in patients with those 2 g in patients with serum Tg lt 10 ng dL or serum TgAb lt 100 IU mL were better than in patients with those 10 ng dL or 100 IU mL respectively. Conclusion The treatment effectiveness of 131I with low dose 30 50 mCi was equivalent to high dose of 100 mCi in patients with no distant .